1
|
Baltgalvis KA, Lamb KN, Symons KT, Wu CC, Hoffman MA, Snead AN, Song X, Glaza T, Kikuchi S, Green JC, Rogness DC, Lam B, Rodriguez-Aguirre ME, Woody DR, Eissler CL, Rodiles S, Negron SM, Bernard SM, Tran E, Pollock J, Tabatabaei A, Contreras V, Williams HN, Pastuszka MK, Sigler JJ, Pettazzoni P, Rudolph MG, Classen M, Brugger D, Claiborne C, Plancher JM, Cuartas I, Seoane J, Burgess LE, Abraham RT, Weinstein DS, Simon GM, Patricelli MP, Kinsella TM. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature 2024:10.1038/s41586-024-07318-y. [PMID: 38658751 DOI: 10.1038/s41586-024-07318-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 03/14/2024] [Indexed: 04/26/2024]
Abstract
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with faulty mismatch repair mechanisms1-5. Currently there are no approved drugs directly targeting human DNA or RNA helicases, in part owing to the challenging nature of developing potent and selective compounds to this class of proteins. Here we describe the chemoproteomics-enabled discovery of a clinical-stage, covalent allosteric inhibitor of WRN, VVD-133214. This compound selectively engages a cysteine (C727) located in a region of the helicase domain subject to interdomain movement during DNA unwinding. VVD-133214 binds WRN protein cooperatively with nucleotide and stabilizes compact conformations lacking the dynamic flexibility necessary for proper helicase function, resulting in widespread double-stranded DNA breaks, nuclear swelling and cell death in MSI-high (MSI-H), but not in microsatellite-stable, cells. The compound was well tolerated in mice and led to robust tumour regression in multiple MSI-H colorectal cancer cell lines and patient-derived xenograft models. Our work shows an allosteric approach for inhibition of WRN function that circumvents competition from an endogenous ATP cofactor in cancer cells, and designates VVD-133214 as a promising drug candidate for patients with MSI-H cancers.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Betty Lam
- Vividion Therapeutics, San Diego, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Piergiorgio Pettazzoni
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Markus G Rudolph
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Moritz Classen
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Doris Brugger
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Christopher Claiborne
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Jean-Marc Plancher
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Isabel Cuartas
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Joan Seoane
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| | | | - Robert T Abraham
- Vividion Therapeutics, San Diego, CA, USA
- Odyssey Therapeutics, San Diego, CA, USA
| | | | | | | | | |
Collapse
|
2
|
Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini VG, Freimoser-Grundschober A, Cuartas I, Martinez-Moreno A, Martinez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia X, Fahrni L, Poeschinger T, Steinhart V, Richard M, Briner S, Mueller JP, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, Gonzalez J, Nuciforo PG, Carles J, Vieito M, Tabernero J, Umana P, Seoane J. A novel EGFRvIII-T cell bispecific antibody for the treatment of glioblastoma. Mol Cancer Ther 2022; 21:1499-1509. [PMID: 35915983 DOI: 10.1158/1535-7163.mct-22-0201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 06/13/2022] [Accepted: 07/22/2022] [Indexed: 11/16/2022]
Abstract
T cell bispecific antibodies (TCBs) are engineered molecules that bind both the T cell receptor and tumor-specific antigens. Epidermal growth factor receptor variant III (EGFRvIII) mutation is a common event in glioblastoma (GBM) and is characterized by the deletion of exons 2-7, resulting in a constitutively active receptor that promotes cell proliferation, angiogenesis and invasion. EGFRvIII is expressed on the surface of tumor cells and is not expressed in normal tissues making EGFRvIII an ideal neoantigen target for TCBs. We designed and developed a novel 2+1 EGFRvIII-TCB with optimal pharmacological characteristics and potent anti-tumor activity. EGFRvIII-TCB showed specificity for EGFRvIII and promoted tumor cell killing as well as T cell activation and cytokine secretion only in patient-derived models expressing EGFRvIII. Moreover, EGFRvIII-TCB promoted T cell recruitment into intracranial tumors. EGFRvIII-TCB induced tumor regression in GBM animal models, including humanized orthotopic GBM patient-derived xenograft (PDX) models. Our results warrant the clinical testing of EGFRvIII-TCB for the treatment of EGFRvIII-expressing GBMs.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Anne Freimoser-Grundschober
- Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Wagistrasse 10, CH-8952 Schlieren, Schlieren, Switzerland
| | - Isabel Cuartas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | | | | | | | | | | | - Xavier Guardia
- Vall dHebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Linda Fahrni
- Roche Innovation Center Zurich, Schlieren, Switzerland
| | | | | | - Marine Richard
- Roche Innovation Center Z�rich, Schlieren, Outside U.S. & Canada, Switzerland
| | - Stefanie Briner
- Roche Innovation Center Zurich (RICZ), Schlieren, Zurich, Switzerland
| | - Joerg Pj Mueller
- Roche Innovation Center Munich (RICM), Penzberg, Munich, Germany
| | - Franz Osl
- Roche Diagnostics GmbH, Penzberg, Germany
| | - Johannes Sam
- Roche Innovation Center Zurich, Roche Pharmaceutical Research & Early Development, pRED, Schlieren, Switzerland
| | - Sara Colombetti
- Roche Innovation Center Z�rich, Schlieren, Outside U.S. & Canada, Switzerland
| | - Marina Bacac
- Roche Innovation Center Zurich, Zurich, Switzerland
| | | | | | | | - Alberto Di Somma
- IDIBAPS Advances in Neurosurgery Research Group, Barcelona, Spain
| | - Josep Gonzalez
- Hospital Clinic, University of Barcelona and Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | - Joan Carles
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - María Vieito
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Josep Tabernero
- Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Pablo Umana
- Roche Innovation Center Zurich, Zurich, Switzerland
| | - Joan Seoane
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| |
Collapse
|
3
|
Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuéndez M, Cordero E, Topczewski TE, Ferrés-Pijoan A, Gonzalez J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J. Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis. Cancer Res 2022; 82:2552-2564. [PMID: 35584009 DOI: 10.1158/0008-5472.can-21-4152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 02/23/2022] [Accepted: 05/13/2022] [Indexed: 11/16/2022]
Abstract
The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K-mutated melanoma is limited and transient. Resistance largely occurs through the restoration of MAPK signaling via paradoxical BRAF activation, highlighting the need for more effective therapeutic options. Aiming to address this clinical challenge, we characterized the activity of a potent, brain-penetrant paradox breaker BRAFi (compound 1a, C1a) as first line therapy and following progression upon treatment with approved BRAFi and BRAFi/MEKi therapies. C1a activity was evaluated in vitro and in vivo in melanoma cell lines and patient-derived models of BRAF V600E-mutant melanoma brain metastases following relapse after treatment with BRAFi/MEKi. C1a showed superior efficacy compared to approved BRAFi, both in subcutaneous and brain metastatic models. Importantly, C1a manifested potent and prolonged antitumor activity even in models that progressed on BRAFi/MEKi treatment. Analysis of mechanisms of resistance to C1a revealed MAPK reactivation under drug treatment as the predominant resistance-driving event in both subcutaneous and intracranial tumors. Specifically, BRAF kinase domain duplication was identified as a frequently occurring driver of resistance to C1a. Combination therapies of C1a and anti-PD1 antibody proved to significantly reduce disease recurrence. Collectively, these preclinical studies validate the outstanding antitumor activity of C1a in brain metastasis, support clinical investigation of this agent in patients pretreated with BRAFi/MEKi, unveil genetic drivers of tumor escape from C1a, and identify a combinatorial treatment that achieves long-lasting responses.
Collapse
Affiliation(s)
| | | | | | | | | | - Isabel Cuartas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | | | | | | | | | | | | | | | | | - Romi Feddersen
- Roche Pharma Research & Early Development pRED, Roche Innovation Center Munich, Penzberg, Germany., Penzberg, Germany
| | | | | | | | | | - Thomaz E Topczewski
- Hospital Clinic, University of Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Abel Ferrés-Pijoan
- Hospital Clinic, University of Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Josep Gonzalez
- Hospital Clinic, University of Barcelona and Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Spain
| | | | - Eva Muñoz-Couselo
- Vall d'Hebron Institute of Oncology, barcelona, barcelona, spain, Spain
| | - Josep Tabernero
- Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | - Joan Seoane
- Vall d Hebron Institute of Oncology (VHIO), Barcelona, Spain
| |
Collapse
|
4
|
Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci Transl Med 2018; 10:eaat1445. [PMID: 30282693 PMCID: PMC6498439 DOI: 10.1126/scitranslmed.aat1445] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 06/15/2018] [Accepted: 09/07/2018] [Indexed: 12/20/2022]
Abstract
T cell bispecific antibodies (TCBs) are engineered molecules that include, within a single entity, binding sites to the T cell receptor and to tumor-associated or tumor-specific antigens. The receptor tyrosine kinase HER2 is a tumor-associated antigen in ~25% of breast cancers. TCBs targeting HER2 may result in severe toxicities, likely due to the expression of HER2 in normal epithelia. About 40% of HER2-positive tumors express p95HER2, a carboxyl-terminal fragment of HER2. Using specific antibodies, here, we show that p95HER2 is not expressed in normal tissues. We describe the development of p95HER2-TCB and show that it has a potent antitumor effect on p95HER2-expressing breast primary cancers and brain lesions. In contrast with a TCB targeting HER2, p95HER2-TCB has no effect on nontransformed cells that do not overexpress HER2. These data pave the way for the safe treatment of a subgroup of HER2-positive tumors by targeting a tumor-specific antigen.
Collapse
Affiliation(s)
- Irene Rius Ruiz
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
| | - Rocio Vicario
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Beatriz Morancho
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
| | - Cristina Bernadó Morales
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
| | - Enrique J Arenas
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Sylvia Herter
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Anne Freimoser-Grundschober
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Jitka Somandin
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Johannes Sam
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Oliver Ast
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | | | - Antonio Luque
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Marta Escorihuela
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Ismael Varela
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Isabel Cuartas
- Translational Research Program, VHIO, 08035 Barcelona, Spain
| | | | | | - Vicente Peg
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
- Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Isabel Rubio
- Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Javier Cortés
- Clinical Research Program, VHIO, 08035 Barcelona, Spain
| | - Violeta Serra
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
| | - Santiago Escriva-de-Romani
- Clinical Research Program, VHIO, 08035 Barcelona, Spain
- Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Jeff Sperinde
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA
| | - Ahmed Chenna
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA
| | - Weidong Huang
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA
| | - John Winslow
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA
| | - Joan Albanell
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
- Medical Oncology Service, Hospital del Mar, 08003 Barcelona, Spain
- Universitat Pompeu Fabra, 08003 Barcelona, Spain
| | - Joan Seoane
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
- Translational Research Program, VHIO, 08035 Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain
- Institució Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain
| | - Maurizio Scaltriti
- Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Jose Baselga
- Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Josep Tabernero
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
- Clinical Research Program, VHIO, 08035 Barcelona, Spain
- Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Pablo Umana
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Marina Bacac
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Cristina Saura
- Clinical Research Program, VHIO, 08035 Barcelona, Spain
- Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Christian Klein
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland
| | - Joaquín Arribas
- Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain
- Institució Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain
| |
Collapse
|
5
|
Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, Ha PK, Murnane J, Cuartas I, Seoane J, Baumann M, Linge A, Barcellos-Hoff MH. Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. Clin Cancer Res 2018; 24:6001-6014. [PMID: 30087144 DOI: 10.1158/1078-0432.ccr-18-1346] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 06/15/2018] [Accepted: 08/02/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE Following cytotoxic therapy, 70% of patients with human papillomavirus (HPV)-positive oropharyngeal head and neck squamous cell carcinoma (HNSCC) are alive at 5 years compared with 30% of those with similar HPV-negative cancer. Loss of TGFβ signaling is a poorly studied consequence of HPV that could contribute to patient outcome by compromising DNA repair. EXPERIMENTAL DESIGN Human HNSCC cell lines (n = 9), patient-derived xenografts (n = 9), tissue microarray (n = 194), TCGA expression data (n = 279), and primary tumor specimens (n = 10) were used to define the relationship between TGFβ competency, response to DNA damage, and type of DNA repair. RESULTS Analysis of HNSCC specimens in situ and in vitro showed that HPV associated with loss of TGFβ signaling that increased response to radiation or cisplatin. TGFβ suppressed miR-182, which inhibited both BRCA1, necessary for homologous recombination repair (HRR), and FOXO3, required for ATM kinase activity. TGFβ signaling blockade by either HPV or inhibitors released miR182 control, compromised HRR and increased response to PARP inhibition. Antagonizing miR-182 rescued the HRR deficit in HPV-positive cells. Loss of TGFβ signaling unexpectedly increased repair by error prone, alternative end-joining (alt-EJ). CONCLUSIONS HPV-positive HNSCC cells are unresponsive to TGFβ. Abrogated TGFβ signaling compromises repair by HRR and increases reliance on alt-EJ, which provides a mechanistic basis for sensitivity to PARP inhibitors. The effect of HPV in HNSCC provides critical validation of TGFβ's role in DNA repair proficiency and further raises the translational potential of TGFβ inhibitors in cancer therapy.
Collapse
Affiliation(s)
- Qi Liu
- Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
| | - Lin Ma
- Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
| | - Trevor Jones
- Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
| | - Luis Palomero
- ProCURE, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - Miquel Angel Pujana
- ProCURE, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | | | - Patrick K Ha
- Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
| | - John Murnane
- Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
| | - Isabel Cuartas
- Vall d Hebron Institute of Oncology (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Joan Seoane
- Vall d Hebron Institute of Oncology (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Michael Baumann
- German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Consortium (DKTK), Partner Site Dresden, Germany; and Department of Radiotherapy and Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
| | - Annett Linge
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Mary Helen Barcellos-Hoff
- Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
| |
Collapse
|
6
|
Huber-Ruano I, Raventós C, Cuartas I, Sánchez-Jaro C, Arias A, Parra JL, Wosikowski K, Janicot M, Seoane J. An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Ann Oncol 2018; 28:2278-2285. [PMID: 28911087 DOI: 10.1093/annonc/mdx314] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Background The transforming growth factor (TGF)-β pathway is a well-described inducer of immunosuppression and can act as an oncogenic factor in advanced tumors. Several preclinical and clinical studies show that the TGF-β pathway can be considered a promising molecular target for cancer therapy. The human genome has three TGF-β isoforms and not much is known about the oncogenic response to each of the isoforms. Here, we studied the antitumor response to ISTH0047, a recently developed locked nucleic acid-modified antisense oligonucleotide targeting TGF-β2. Materials and methods We have studied the anticancer response to ISTH0047 using gymnotic delivery in tumor cell cultures and in in vivo preclinical orthotopic mouse models for primary tumors (breast and kidney tumors) and lung metastasis. Results We observed that ISTH0047 is able to significantly reduce TGF-β2 mRNA and protein levels without altering the levels of TGF-β1 and TGF-β3. ISTH0047 prevented lung metastasis in syngeneic orthotopic renal cell carcinoma (RENCA) and breast cancer (4T1) tumor models. In addition, using an orthotopic xenograft model of a lung cancer cell line (CRL5807) that mainly expresses TGF-β2, we observed that ISTH0047 had an important effect on the lung microenvironment inhibiting the growth of lung lesions. ISTH0047 treatment re-educated macrophages in the lung parenchyma to express the tumor-suppressive factor, CD86. Conclusion Overall, our data point to TGF-β2 as a therapeutic target and ISTH0047 as a novel anticancer drug to prevent lung metastasis by impacting on the tumor niche, in part, through the induction of CD86 in tumor-associated macrophages.
Collapse
Affiliation(s)
- I Huber-Ruano
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona
| | - C Raventós
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona
| | - I Cuartas
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona
| | - C Sánchez-Jaro
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona
| | - A Arias
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona
| | - J L Parra
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona
| | | | - M Janicot
- Isarna Therapeutics, Munich, Germany
| | - J Seoane
- Translational Research Program, Vall d Hebron Institute of Oncology (VHIO), Barcelona.,Universitat Autònoma de Barcelona, Cerdanyola del Vallès.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| |
Collapse
|
7
|
Ruano IH, Raventós C, Arias A, Cascante A, Cuartas I, Seoane J. TGFβ-induced JMJD3 controls tumor cell microenvironment and myeloid cell polarization. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61227-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Parra J, Mayor R, Huber I, Cuartas I, Arias A, Raventós C, Seoane J. Similarities between the Marfan syndrome and cancer: Implications of the Fibrillin-TGFβ axis on cancer biology and treatment. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61676-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun 2014; 5:4632. [PMID: 25130259 PMCID: PMC4143920 DOI: 10.1038/ncomms5632] [Citation(s) in RCA: 130] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Accepted: 07/09/2014] [Indexed: 12/21/2022] Open
Abstract
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. Using the Myc dominant negative Omomyc, we previously showed that Myc inhibition is a promising strategy for cancer therapy. Here, we preclinically validate Myc inhibition as a therapeutic strategy in mouse and human glioma, using a mouse model of spontaneous multifocal invasive astrocytoma and its derived neuroprogenitors, human glioblastoma cell lines, and patient-derived tumours both in vitro and in orthotopic xenografts. Across all these experimental models we find that Myc inhibition reduces proliferation, increases apoptosis and remarkably, elicits the formation of multinucleated cells that then arrest or die by mitotic catastrophe, revealing a new role for Myc in the proficient division of glioma cells. Myc has been implicated in the development of multiple types of cancer. Here, the authors explore the therapeutic potential and mechanism of action of Myc inhibition in mouse and human models of glioblastoma, an aggressive type of tumour that is often resistant to conventional therapy.
Collapse
Affiliation(s)
- Daniela Annibali
- 1] Department of Pathology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA [2] Istituto di Biologia, Medicina Molecolare e NanoBiotecnologie, C.N.R., Dipartimento di Biologia e Biotecnologie, Università La Sapienza, 00185 Rome, Italy [3]
| | - Jonathan R Whitfield
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain [3]
| | - Emilia Favuzzi
- Istituto di Biologia, Medicina Molecolare e NanoBiotecnologie, C.N.R., Dipartimento di Biologia e Biotecnologie, Università La Sapienza, 00185 Rome, Italy
| | - Toni Jauset
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Erika Serrano
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Isabel Cuartas
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Sara Redondo-Campos
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Gerard Folch
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Alba Gonzàlez-Juncà
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Nicole M Sodir
- 1] Department of Pathology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA [2] Department of Biochemistry, Sanger Building, University of Cambridge, Cambridge CB2 1QW, UK
| | - Daniel Massó-Vallés
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Marie-Eve Beaulieu
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| | - Lamorna B Swigart
- Department of Pathology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
| | - Margaret M Mc Gee
- UCD School of Biomolecular &Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
| | - Maria Patrizia Somma
- Istituto di Biologia, Medicina Molecolare e NanoBiotecnologie, C.N.R., Dipartimento di Biologia e Biotecnologie, Università La Sapienza, 00185 Rome, Italy
| | - Sergio Nasi
- Istituto di Biologia, Medicina Molecolare e NanoBiotecnologie, C.N.R., Dipartimento di Biologia e Biotecnologie, Università La Sapienza, 00185 Rome, Italy
| | - Joan Seoane
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain [3] Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Gerard I Evan
- Department of Biochemistry, Sanger Building, University of Cambridge, Cambridge CB2 1QW, UK
| | - Laura Soucek
- 1] Vall d'Hebron Institute of Oncology (VHIO), Edifici Mediterrània, Hospital Vall d'Hebron, 08035 Barcelona, Spain [2] Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), 08193 Barcelona, Spain
| |
Collapse
|
10
|
Junca AG, Sanchez-Redondo S, Cuartas I, Seoane J. 466 Study of the Glioma Initiating Cells CD44high/ID1high in Glioblastoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71139-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 2010; 18:655-68. [PMID: 21156287 DOI: 10.1016/j.ccr.2010.10.023] [Citation(s) in RCA: 440] [Impact Index Per Article: 31.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2010] [Revised: 07/09/2010] [Accepted: 09/27/2010] [Indexed: 01/06/2023]
Abstract
Glioma-initiating cells (GICs), also called glioma stem cells, are responsible for tumor initiation, relapse, and therapeutic resistance. Here, we show that TGF-β inhibitors, currently under clinical development, target the GIC compartment in human glioblastoma (GBM) patients. Using patient-derived specimens, we have determined the gene responses to TGF-β inhibition, which include inhibitors of DNA-binding protein (Id)-1 and -3 transcription factors. We have identified a cell population enriched for GICs that expresses high levels of CD44 and Id1 and tend to be located in a perivascular niche. The inhibition of the TGF-β pathway decreases the CD44(high)/Id1(high) GIC population through the repression of Id1 and Id3 levels, therefore inhibiting the capacity of cells to initiate tumors. High CD44 and Id1 levels confer poor prognosis in GBM patients.
Collapse
Affiliation(s)
- Judit Anido
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Folch G, Prieto-Sánchez R, Cuartas I, Raventós C, Seoane J. 40 TGFβ receptor inhibitors target the CD44high/Id1high glioma stem cell population in human glioblastoma. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70849-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
13
|
Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15:315-27. [PMID: 19345330 DOI: 10.1016/j.ccr.2009.02.011] [Citation(s) in RCA: 397] [Impact Index Per Article: 26.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2008] [Revised: 09/14/2008] [Accepted: 02/06/2009] [Indexed: 12/28/2022]
Abstract
Glioma-initiating cells (GICs) are responsible for the initiation and recurrence of gliomas. Here, we identify a molecular mechanism that regulates the self-renewal capacity of patient-derived GICs. We show that TGF-beta and LIF induce the self-renewal capacity and prevent the differentiation of GICs. TGF-beta induces the self-renewal capacity of GICs, but not of normal human neuroprogenitors, through the Smad-dependent induction of LIF and the subsequent activation of the JAK-STAT pathway. The effect of TGF-beta and LIF on GICs promotes oncogenesis in vivo. Some human gliomas express high levels of LIF that correlate with high expression of TGF-beta2 and neuroprogenitor cell markers. Our results show that TGF-beta and LIF have an essential role in the regulation of GICs in human glioblastoma.
Collapse
Affiliation(s)
- Silvia Peñuelas
- Medical Oncology Program, Vall d'Hebron University Hospital Research Institute, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Suelves M, Vidal B, Ruiz V, Baeza-Raja B, Diaz-Ramos A, Cuartas I, Lluis F, Parra M, Jardi M, Lopez-Alemany R, Serrano AL, Munoz-Canoves P. The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (upa) and its inhibitor (PAI-1). FRONT BIOSCI-LANDMRK 2005; 10:2978-85. [PMID: 15970552 DOI: 10.2741/1754] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The plasminogen activation (PA) system is an extensively used mechanism for the generation of proteolytic activity in the extracellular matrix, where it contributes to tissue remodeling in a wide range of physiopathological processes. Despite the limited information available at present on plasminogen activators, their inhibitors and cognate receptors in skeletal muscle, increasing evidence is accumulating on their important roles in the homeostasis of muscle fibers and their surrounding extracellular matrix. The development of mice deficient for the individual components of the PA system has provided an incisive approach to test the proposed muscle functions in vivo. Skeletal muscle regeneration induced by injury has been analyzed in urokinase-type plasminogen activator (uPA)-, tissue-type plasminogen activator (tPA)-, plasminogen (Plg)- and plasminogen activator inhibitor-1 (PAI-1)-deficient mice and has demonstrated profound effects of these molecules on the fibrotic state and the inflammatory response, which contribute to muscle repair. In particular, the opposite roles of uPA and its inhibitor PAI-1 in this process are highlighted. Delineating the mechanisms by which the different plasminogen activation system components regulate tissue repair will be of potential therapeutic value for severe muscle disorders.
Collapse
Affiliation(s)
- Monica Suelves
- Program on Differentiation and Cancer, Center for Genomic Regulation, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|